By: Stephen Del Percio , AECOM National governments globally are struggling to enact legislation that will bind them to the world’s carbon dioxide and other greenhouse gas emissions reduction targets, and unfortunately in some cases even reach...

Access Lexis Practice Advisor’s complimentary Coronavirus (COVID-19) Resource Kit here. Lexis Practice Advisor subscribers may access the Coronavirus Resource Kit here. Not a subscriber? Follow this link to sign up for free access to the Coronavirus...

For an overview of current practical guidance on generative AI, ChatGPT, and similar tools, see Generative Artificial Intelligence (AI) Resource Kit LexisNexis is pioneering the use of generative AI with Lexis+ AI™, focusing on reliability...

By: Michael Furrow , DLA Piper, and Whitney Meier , Venable LLP The Biologics Price Competition and Innovation Act (BPCIA) provides an abbreviated pathway for companies to bring biologic drugs to market that are biosimilar to previously approved branded...

LexisNexis is taking steps to keep the public informed during the coronavirus/COVID-19 pandemic by providing free access to information and resources around the world through company platforms and outlets. Key among the resources are the Lexis Practice...